StemBioSys, Inc. news

Privately-held StemBioSys, Inc., based in San Antonio, announced today that it had closed on an oversubscribed $6.6 million Series C Preferred Stock financing in August. According to StemBioSys CEO Bob Hutchens, the company is investing the proceeds to support the ongoing development and commercialization of its proprietary technologies. In November of 2020, StemBioSys announced the publication of data demonstrating that its CELLvo Matrix Plus Technology supports development of an advan

Dr. Jeanne Loring, Professor Emeritus of The Scripps Research Institute, Founding Director of the Center for Regenerative Medicine at Scripps, and founder of Aspen Neuroscience, has joined the Scientific Advisory Board of StemBioSys, Inc., (SBS) a privately-held, San Antonio-based biomedical company focused on a broad range of cell-based products.

StemBioSys CEO Bob Hutchens made the announcement, noting “Dr. Loring brings extraordinary research credentials to our Scientific Adv

StemBioSys, Inc. (StemBioSys) and CarTox, Inc. (Cartox) announced today the publication of research in Nature Scientific Reports demonstrating that CELLvo™ Matrix Plus, an extracellular matrix (ECM) technology derived from human perinatal stem cells, supports rapid functional and structural maturation of human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) in culture and enables high throughput cardiotoxicity screening using mature human cardiomyocytes.

StemBioSys introduced a new culture system designed to help investigators grow human chondrocytes in vitro faster while retaining a natural phenotype. The kit is comprised of CELLvo™ Matrix, a cell-derived extracellular matrix that mimics the chondrocytes’ natural microenvironment, and CELLvo™ Human Articular Chondrocytes, a collection of human chondrocytes sourced from donors of different ages and health statuses. When CELLvo™ Chondrocytes are cultured on CELLvo&trade